Focused On-demand Library for GPI mannosyltransferase 2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q9NUD9

UPID:

PIGV_HUMAN

Alternative names:

GPI mannosyltransferase II; Phosphatidylinositol-glycan biosynthesis class V protein

Alternative UPACC:

Q9NUD9; D3DPL2; Q5JYG7; Q5JYG8; Q5JYG9; Q9NX26

Background:

GPI mannosyltransferase 2, also known as GPI mannosyltransferase II and Phosphatidylinositol-glycan biosynthesis class V protein, plays a crucial role in glycosylphosphatidylinositol-anchor biosynthesis. This enzyme is responsible for transferring the second mannose to the glycosylphosphatidylinositol during GPI precursor assembly, a key step in cell surface protein anchoring.

Therapeutic significance:

The protein is linked to Hyperphosphatasia with impaired intellectual development syndrome 1, a severe syndrome characterized by elevated serum alkaline phosphatase, intellectual disability, and more. Understanding the role of GPI mannosyltransferase 2 could open doors to potential therapeutic strategies for this syndrome.